Fewer than a tenth of individuals who could benefit from weight-loss injections like Wegovy are able to get them, states the World Health Organization as it releases its first advice on the medications.
Given in excess of 1,000,000,000 people worldwide currently obese, it is urging increased and just availability to this class of drugs.
Based on estimates, over two billion are projected to be living with obesity by 2030 without intervention.
"The new guidelines recognises that obesity is a long-term condition that can be addressed with comprehensive and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are significant barriers to broad access to the treatments that can aid individuals in losing substantial body mass, says the body.
Skinny Jab Scarcity
Even in the current most optimistic outlook, the production of these medications would only suffice for about 100 million people – fewer than 10% of eligible patients, according to the WHO.
The advice urges governments and firms to increase availability, by approaches including voluntary licensing.
A patent on the active ingredient – the primary component of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
How Obesity Jabs Operate
The injections mimick a body's own hormone to delay gastric emptying, reduce hunger and enhance the sense of being full so individuals eat less.
Individuals usually start to lose weight within a few weeks of starting on the regular doses.
Evidence points to users may put most of the weight back on after a year of halting the drug, when their normal food cravings return.
Being carrying excess weight increases your risk for experiencing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight concerns people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
